Aberdeen scientists to explore African seas for drug discoveries
Research could lead to new treatments for cancer and MRSA
A team will travel to Ghana next month to search the waters for unique marine organisms that could be used to develop new medicines.
The scientists hope to find previously undiscovered species of corals, sponges and sea squirts. They will examine these organisms for new molecules, bacteria and fungi, which could be used in the creation of new treatments for diseases prevalent in Africa – including tuberculosis and parasitic diseases such as malaria.
Professor Marcel Jaspars, director of the Marine Biodiscovery Centre, said: ‘Drug discovery work in West Africa has historically focused on land, investigating how molecules in plants can be used in the development of new medicines.
‘Our project marks the first time waters off the coast of West Africa have been explored to assess the diversity of marine organisms available in this area, and the potential they could harbour in the treatment of a number of diseases.’
Jaspars said the team would collect samples at low tide around the Gulf of Guinea and Guinea Basin, where they believe they will find new species.
The Aberdeen scientists will work with the University of Ghana during the trip, which marks the beginning of a three-year collaborative project between the two institutions.
The £1.6m Marine Biodiscovery Centre – which brings together chemists and biologists to work on the development of new pharmaceuticals from organisms from the depths of the world’s oceans – opened in June. It is one of only three in Europe dedicated to the exploration of the natural resources from our seas.
The project is funded by the Leverhulme Trust and co-ordinated by the Royal Society.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
UK clinical trial reforms come into force in largest regulatory overhaul in 20 years
Read moreThe MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Trending Articles
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
UK clinical trial reforms come into force in largest regulatory overhaul in 20 years
The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Research & Development
Epitopea receives MHRA approval for first-in-human trial of RNA vaccine for ovarian cancer
The company has received regulatory approval from the MHRA and Regional Ethics Committee to initiate its OVACT Phase I/Ib clinical trial of CryptiVax-1001, an off-the-shelf mRNA immunotherapy targeting high-grade serous ovarian cancer
Research & Development
NEUVIOR Pharmaceuticals receives Innovate UK grant to explore bio-based materials for circular pharmaceutical manufacturing
The Innovate UK feasibility grant will advance its ZYLON programme, which involves clean-chemistry lab trials exploring how bio-derived materials could replace harder-to-recycle packaging formats and reduce waste in pharmaceutical manufacturing
Research & Development
Awen Oncology secures seven-figure funding to advance rare bone cancer therapeutic programme
The cancer therapeutics company has secured seven-figure funding led by biotech investor Dr Urs Spitz to progress its lead programme targeting a rare form of bone cancer with potential broader oncology applications towards clinical development
Research & Development
Leinco Technologies and CellCarta partner to advance proteomics solutions for discovery and drug development
The pair have announced a strategic collaboration combining Leinco's IHC and spatial biology-validated antibody portfolio with CellCarta's CPTAC-validated Immuno-MRM assay resources to enhance proteomic analysis for immuno-oncology and targeted therapy development
Research & Development
Biognosys collaborates with Michael J. Fox Foundation to develop biomarker assays for Parkinson's research
The pair will work to develop highly sensitive, quantitative biomarker assays targeting LRRK2, the most common genetic risk factor for late-onset Parkinson's disease, in support of the foundation's global LITE initiative spanning more than 50 academic, industry and clinical partners